Exelixis Inc. (NASDAQ:EXEL) is one of the best low priced growth stocks to invest in now. On May 5, Exelixis reported total revenues of $610.8 million for Q1 2026, up from $555.4 million in Q1 2025. This increase was driven primarily by US net product revenues of $555 million from its cabozantinib franchise, alongside a rise in collaboration revenues to $55.8 million. The company achieved a GAAP net income of $210.5 million ($0.79 diluted EPS) and a non-GAAP net income of $232.8 million ($0.87 diluted EPS), while maintaining its full-year 2026 financial guidance.
On the clinical and regulatory front, the US FDA accepted Exelixis’ first NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, setting a target action date of December 3. The company expanded its GI sales team to support this pipeline and continued progressing…
